New drug combo aims to improve leukemia treatment in young adults
NCT ID NCT07651176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which combination leads to the longest time without the cancer returning or getting worse. Participants are randomly assigned to one of three treatment groups and followed for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lisaftoclax, daunorubicin, cytarabine, homoharringtonine, aclarubicin
What this could lead to
If successful, this could identify a more effective chemotherapy combination for young adults with low-risk AML, potentially improving long-term survival without relapse.
What could go wrong
This is a mid-stage trial, so results may not confirm superiority. Adding lisaftoclax could increase side effects like bone marrow suppression or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China